CagriSema Combination Therapy Explored for Weight Loss in Chinese Adults

Globally, obesity and overweight are escalating public health crises, significantly increasing the risk of chronic conditions like type 2 diabetes and cardiovascular disease. While GLP-1 receptor agonists, such as semaglutide, have revolutionized weight management, there's a continuous search for even more effective interventions. Amylin analogs like cagrilintide also contribute to satiety and weight loss through distinct mechanisms. This Phase 3 trial investigates whether combining these two powerful mechanisms in CagriSema offers superior weight reduction compared to semaglutide alone in a Chinese population.

This Phase 3 clinical trial, which completed data collection in February 2025, aimed to demonstrate the superior efficacy of CagriSema over semaglutide alone and placebo for weight reduction in Chinese adults. While specific results from this trial are currently pending publication, the study's primary endpoint is designed to measure the percentage change in body weight from baseline to week 44. Secondary endpoints are expected to include the proportion of participants achieving 5%, 10%, and 15% weight loss, along with changes in metabolic markers and safety profiles. It is anticipated, based on prior research, that CagriSema will demonstrate a statistically significant greater weight loss compared to semaglutide 2.4 mg monotherapy and placebo, leveraging the synergistic effects of its two components. > The trial is designed to show that CagriSema leads to a substantially greater percentage of body weight reduction compared to semaglutide 2.4 mg alone over 44 weeks in 300 Chinese participants with overweight or obesity.